Mangoceuticals, Inc.
MGRX
$2.49
-$0.08-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 105.20K | 133.40K | 163.20K | 214.10K | 244.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.20K | 133.40K | 163.20K | 214.10K | 244.40K |
| Cost of Revenue | 25.10K | 50.70K | 93.40K | 66.70K | 101.80K |
| Gross Profit | 80.10K | 82.70K | 69.80K | 147.40K | 142.60K |
| SG&A Expenses | 1.74M | 1.59M | 1.96M | 2.07M | 2.39M |
| Depreciation & Amortization | 721.50K | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.49M | 1.64M | 2.29M | 2.30M | 2.49M |
| Operating Income | -2.38M | -1.50M | -2.13M | -2.09M | -2.24M |
| Income Before Tax | -1.95M | -2.00M | -2.39M | -2.37M | -2.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.95M | -2.00M | -2.39M | -2.37M | -2.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00 | 500.00 | 300.00 | 0.00 | -- |
| Net Income | -1.95M | -2.00M | -2.39M | -2.37M | -2.57M |
| EBIT | -2.38M | -1.50M | -2.13M | -2.09M | -2.24M |
| EBITDA | -1.66M | -1.50M | -2.13M | -2.08M | -2.24M |
| EPS Basic | -1.08 | -0.99 | -1.37 | -1.56 | -1.96 |
| Normalized Basic EPS | -0.46 | -0.62 | -0.86 | -0.97 | -1.22 |
| EPS Diluted | -1.08 | -0.99 | -1.37 | -1.56 | -1.96 |
| Normalized Diluted EPS | -0.46 | -0.62 | -0.86 | -0.97 | -1.22 |
| Average Basic Shares Outstanding | 2.62M | 2.01M | 1.74M | 1.52M | 1.31M |
| Average Diluted Shares Outstanding | 2.62M | 2.01M | 1.74M | 1.52M | 1.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |